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Scleroderma, which follows rheumatoid arthritis and systemic lupus erythematosus 
as  the  third  most  prevalent  rheumatic  disorder,  is  poorly understood.  Connective 
tissue abnormalities have been explored extensively (1); recently, vascular involvement 
has been emphasized as a unifying pathogenetic concept (2, 3). The vascular features 
in  scleroderma include  Raynaud's  phenomenon;  an early, edematous phase of the 
disorder; telangiectasia; capillary abnormalities as seen by nailfold and uhrastructural 
microscopy; and  widespread  vascular pathology noted in  all  involved organs.  The 
most  striking  histological  abnormalities  occur in  small  arteries  and  arterioles  and 
consist of distinctive intimal proliferation of cells arranged concentrically in a matrix 
of ground substance;  the cells are thought  to originate from medial smooth muscle 
and to migrate toward the intima after injury to the endothelium (4).  Evidence for 
endothelial injury includes: (a) the disappearance of endothelium in association with 
thrombosis or fibrinoid necrosis in ultrastructural studies; (b) the absence of endothe- 
lial cells within the thickened intima (4, 3)  the duplication of basement membrane, 
a common observation in scleroderma and known to occur after endothelial pertur- 
bation in other settings. 
The ability to isolate, characterize, and maintain endothelial cells in vitro provides 
a  target-cell population  to  study endothelial  damage  in  scleroderma.  The  present 
report describes the effect of scleroderma serum on endothelial, smooth muscle, and 
fibroblast  cell  types.  Sera  from patients  with  scleroderma  (31/52)  and  Raynaud's 
syndrome  (11/19)  contain  cytotoxic activity specific for endothelial  cells which  is 
nondialyzable, heat-stable, and elutes with albumin on gel-filtration chromatography. 
Materials and Methods 
Cell Cultures 
Em)OTHrLIAI. CELL (EC)  I CULTURE.  Cells were obtained from a  human umbilical cord vein 
by adapting the method of Jaffe (5). The vein was washed with balanced salt solution  (BSS, 
pH 7.4) and digested with collagenase (Clostridium histolyticum, grade B, Worthington Biochem- 
ical Corp., Freehold,  N. J., 0.2% in BSS) for 15 min at 37°C and rinsed with BSS. The cells, 
collected  by centrifugation at 250 g for 5 min, were washed  and cultured in F12K medium 
supplemented with 20% fetal calf serum  (FCS, Grand Island  Biochemical  Co., Grand Island, 
N. Y.),  100 U-ml penicillin  and 50/xg/ml gentamicin in plastic Petri dishes (Falcon Labware, 
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Abbreviations used in this paper: BSS, balanced salt solution;  EC,  endothelial cell(s);  FB, fibroblast(s); 
FCS, fetal calf serum; aHTdR, tritium-labeled thymidine; SMC, smooth muscle cell. 
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Div. of Becton, Dickinson, & Co., Oxnard, Calif.) at 37°C  in 5% CO2. Cells were fed twice 
weekly, transferred at confluence, and used for experiments in the first subpassage. 
SMOOTH MUSCLE CELL ($MC) CULTURE.  Cells were obtained from an umbilical cord vein by 
modification of the  technique  for  EC  culture.  Before  collagenase perfusion,  the  cord  was 
traumatized by repeated clamping with a  hemostat. The usual procedure was then followed. 
The cultured, effluent cells yielded a  mixture of endothelial and  long, spindle-shaped cells. 
Within 2-3 wk in culture, a homogeneous population of spindle-shaped cells grew in multiple 
layers. 
FIBROBLAST (Fn) CULTURE.  FB were derived from a  newborn human  foreskin obtained at 
circumcision or from an umbilical cord as follows: Initial sample was trimmed (to remove the 
dermis from skin and the vessels from cord interstitium) and incubated with 0.2% collagenase 
in BSS for 5 h at 37°C, washed three times, resuspended in culture medium, and plated in 35- 
mm Petri dishes. The cells grew out from tissue fragments within 2 wk and reached confluence 
by 4 wk. 
MONONUCLEAR CELL PREPARATION.  Mononuclear cells were isolated by density sedimenta- 
tion  of heparinized  blood  over  Ficol  (Sigma  Chemical  Co.,  St.  Louis,  Mo.)  and  sodium 
diatrizoate (Hypaque  Sodium,  50%,  Winthrop  Laboratories, N.  Y.)  by modification of the 
technique of Boyum (6). Mononuclear cells were resuspended in culture medium at  10  e cells/ 
ml. 
Immunofluorescence Studies.  Cells were grown on glass cover slips for 2-4 d, fixed in acetone, 
air-dried, washed with BSS for 15 rain, incubated with rabbit anti-human factor VIII antigen 
(Behring Diagnostic, American Hoechst Corp., Summerville, N. J.)  for 30 min at 37°C, and 
stained with fluorescein-conjugated goat anti-rabbit gammaglobulin. 
Assay of Cell Growth and Survival 
CELL COUNT.  4  X  104 cells were placed in 35-mm Falcon dishes (Falcon Labware, Div. of 
Becton, Dickinson, & Co.) in F12K culture medium supplemented with 2% FCS and allowed 
to attach overnight. The medium was then replaced with 2 ml F12K medium supplemented 
with test serum. After 72 h, cells were harvested with 0.25%  trypsin-0.01% EDTA and counted 
in a hemocytometer. 
[aH]THYMIDINE (SHTDR]  UPTAKE.  1  X  104  cells were seeded in  Falcon mierotest plates 
(Mierotest 2, Falcon Labware, Div. of Becton, Dickinson, & Co.)  in F12K medium-2% FCS 
and left overnight; the medium was then replaced with F12K medium supplemented with test 
serum.  48  h  later, SHTdR  (6  Ci/mmol,  Schwartz/Mann  Div.,  Beeton,  Dickinson,  &  Co., 
Orangeburg,  N.  Y.)  was  introduced  at  a  1-/~Ci/ml concentration.  24  h  later, medium was 
shaken off the plate, one drop of 0.25%  trypsin-0.01% EDTA was added to each well for 2 rain. 
The cells were harvested on glass-fiber filters (Reeve Angel & Co., Inc., Clifton, N. J.)  and 
washed  with  distilled water,  using  a  semi-automatic cell harvester  (Otto  Hiller Company, 
Madison, Wis.). Filter disks were counted in Aquasol-2 (New England Nuclear, Boston, Mass.) 
on a scintillation counter (Beckman LS-345, Beckman Instruments, Inc., Fullerton, Calif.). 
MmROCYTOTOXlCITV ASSAY.  Using a  one-stage microcytotoxicity technique  (7),  cells were 
harvested, placed in standard microcytotoxicity wells (Microtest, Terasaki Falcon Company) at 
30-40 cells/well in 5/xl F12K medium-2% FCS, and left overnight to attach. The medium was 
then replaced with 5/~1 of test serum. All trays were gently stirred and incubated for 3 h  at 
37°C.  5/xl of dye (Eosin-Y [Fisher Scientific Co., Pittsburgh, Pa.], 5% in BSS) was added to 
each well. After 10 min, cytotoxicity was determined by counting stained cells; toxicity of 20% 
or greater was considered significant. 
Patient Population.  Sera were obtained from 52 patients with scleroderma,  2 19 patients with 
Raynaud's syndrome,  s 24 patients with active connective tissue disease other than scleroderma 
(8 patients with systemic lupus erythematosus, 9 patients with rheumatoid arthritis, 5 patients 
with dermato-polymyositis, 2 patients with polyarteritis nodosa) and 21 healthy controls. Sera 
were heat inactivated (56°C, 30 min) and stored at -70°C. 
Scleroderma was defined as taut skin proximal to the metacarpophalangeal  joints. 
a Raynaud's syndrome  was  defined  as episodic  pallor or cyanosis followed by suffusion, erythema, 
fullness, or pain (without other evidence of rheumatic or connective tissue disease). 1328  ENDOTHELIAL INJURY IN SCLERODERMA 
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FtG.  1.  aHTdR uptake by EC after a 72-h exposure to control and index case serum (LL): LLI, 
serum obtained on presentation; LL2, 3 mo after presentation; and LL3, 5 mo after LL2. Results 
are expressed as mean CPM _  SD of quadruplicate experiments. 
Serum Fructionation.  3 ml of serum equilibrated with Tris(Fisher Scientific Co.)-saline buffer 
(pH  7.6) was  fraetionated  on  a  gel-filtration  column  (Sephadex  G-200,  Pharmacia  Fine 
Chemicals,  Div.  of Pharmaeia  Inc.,  Piscataway,  N. J.);  fractions  were  collected,  dialyzed, 
lyophilized, reconstituted to original volume and used to supplement culture medium. 
Results 
Cell  Identification.  EC  were  identified  and  distinguished  from  SMC  and  FB  by 
morphological  criteria.  Cultured  EC  grew  as  monolayers  of flat,  polygonal  cells, 
required  higher  than  usual  concentration  of serum  for  growth,  and  were  contact 
inhibitable  (8).  In contrast,  SMC  and  FB  grew  as  multilayered  arrays  of spindle- 
shaped cells. In addition, SMC grew in a characteristic hills and valleys pattern which 
was strikingly different from FB and EC (9).  In the present experiments,  EC cultures 
contained >99% factor VIII-positive cells (EC are the only cell type known to produce 
factor VIII antigen  in culture  (10)  and  can  be  definitely  identified  by immunoflu- 
orescent staining with anti-human factor VIII antisera). 
Index Case.  Serum obtained from a  40-yr-old white male (LL1) with a  1 yr history 
ofscleroderma with associated myositis, induced 95% inhibition of EC 3HTdR uptake 
compared to uptake in the presence of an age-, sex-, and race-matched control serum 
(Fig.  l).  3  mo later,  after  prednisone  therapy,  the patient's  serum  (LL2)  showed no 
inhibition  of aHTdR uptake.  At that time, the myositis was inactive clinically.  5 mo 
later,  myositis  recurred  in  association  with  worsening  of the  involved  organs  (skin, 
lung, and esophagus). At that time, serum (LL3) showed 85% inhibition ofEC aHTdR 1329 
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FIG. 2.  aHTdR uptake by FB and SMC after exposure to control and scleroderma (Scl) sera at 10 
and 20% concentrations, lira,  control serum; i, Scl serum. 
uptake.  When  SMC  and  FB were  grown  in  this patient's serum,  no  difference was 
observed in the aHTdR  uptake between the LLI serum and control serum at  10 and 
20% concentrations (Fig. 2). 
Direct cell counts  after  72  h  of exposure to LL1  serum  were  30%  fewer than  the 
original  inoculum,  whereas  control serum  produced  a  100%  increase in  cell count. 
When SMC and FB were used as target cells, there was no difference in the cell count 
between scleroderma serum and control serum  (data not shown). 
When serum concentration in culture medium was increased from 2-30%, aHTdR 
uptake by EC exposed to control serum increased gradually (Fig. 3), whereas uptake 
by EC exposed to scleroderma serum remained low. Differences between control and 
scleroderma  sera  were  most  apparent  at  10-30%  concentrations.  When  sera  were 
mixed in equal parts, the resulting curve was almost identifical to the one induced by 
scleroderma serum alone. The low uptake in the beginning of the curve is a  result of 
low serum concentration (EC require high serum concentrations for proliferation, 15% 
or greater); thus, to avoid the effects of serum deprivation on cells, serum concentra- 
tions consisting of varying proportions of test serum and FCS were held constant at 
20%  in  all dishes  (Fig.  4).  aHTdR  uptake  increased with  increasing control  serum 
concentrations whereas the reverse was observed with scleroderma serum. 
Cytotoxicity  Studies.  Five  cell  types  were  exposed  to  scleroderma  or  control  sera 
(Table I). Significant cellular injury occurred  only when  EC were exposed to scler- 
oderma  serum.  No  significant  toxicity was  seen  with  four  other  target  cell  types. 
Control  sera showed no cytotoxicity. The cytotoxic activity of scleroderma sera was 
stable at 56°C  for 30 min; similar levels of cytotoxicity were observed in scleroderma 
plasma and serum  (data not shown). 
Serum  Fractionation.  Serum  was  fractionated  by  gel-filtration  chromatography 6,000-  EC 
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FIG.  3.  SHTdR uptake by EC after exposure to increasing concentration of control, scleroderma, 
and  1  : 1 mixed sera; each point represents the mean uptake of quadruplicate determinations. Q, 
control serum; O, Scl serum; L~, l:l mixed serum. 
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Fro.  4.  SHTdR  uptake  by EC  after exposure to  increasing relative concentration  of control  or 
scleroderma serum (test serum) and decreasing relative concentration of FCS. Total serum concen- 
tration is kept constant at 20%. Each point represents the mean uptake of quadruplicate wells. O, 
control serum; Q, Scl serum; II, 2% FCS. 
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TABLE  I 
Microcytotoxicity of Control and Scleroderma Sera 
Cells 
Serum 
Control  Scleroderma 
EC  6 :t: 2  52 -4-  14 
SMC  12:1:1.4  12 :t:  1.4 
FB  13:1:3.5  14 :t: 4 
3T3  9.5:1:1  11:1:2.3 
Mononuclear  6 +  0.1  6.5 +  0.5 
Results are expressed as mean percent cells containing dye :1: SD in quadru- 
plicate determinations. Cytotoxicity of 20% or greater is considered  significant. 
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FIG. 5.  Serum fractionation by gel filtration chromatography. Column dimension, 1.5 X 175 cm. 
Flow rate, 5-10 ml/h. Eluant, 50 mM Tris-HC1 (PH 7.6), 5 mM CaClz. Four peaks were observed 
and five fractions were pooled. Fraction I, 30-60 mi, II, 61-75 ml, III, 76-140 ml, IV, 141-180 ml, 
and V, 200-250 ml. Bars represent mean SHTdR uptake by EC after exposure to  15% dialyzed, 
lyophilized but unfractionated (unfr.) sera (scleroderma and control) and to individual fractions. 
~31, Sel serum; I~1, control serum. 
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(Sephadex G-200); four major peaks were observed and all aliquots were pooled into 
five fractions (Fig. 5); each was dialyzed, lyophilized, reconstituted to original volume, 
and used to supplement culture medium at 15% concentration. 3HTdR uptake by EC 
exposed  to  15%  unfractionated, dialyzed,  and  lyophilized serum  showed  that  the 
inhibitory activity is nondialyzable and stable to  lyophilization. Cytotoxie activity 
was observed in fraction 4 and, to a lesser degree, in adjacent fraction 3 of scleroderma 
serum (Fig. 5). 
EC Cytotoxic  Activity  in  Connective  Tissue Disease.  3HTdR uptake by the three cell 
types, EC, SMC, and FB, was determined after exposure to sera at  15% concentration 
from  21  healthy  volunteers, 24  patients with  active  rheumatic disease  other  than 
scleroderma, 52 patients with scleroderma, and 19 patients with Raynaud's syndrome 
alone. 1332  ENDOTHELIAL  INJURY  IN SCLERODERMA 
Ftc.  6.  aHTdR uptake by three cell types. (a) FB, 0a) SMC, and (c) EC. Cells were cultured in the 
presence of 15% test serum. Test sera consisted of 21 healthy volunteers,  24 rheumatic controls  (8 
patients with systemic  lupus erythematosus,  9  with rheumatoid arthritis, and 5  with dermato- 
polymyositis,  2 polyartefitis),  52  patients with scleroderma,  and  19 with  Raynaud's syndrome. 
Shaded area represents  mean uptake by healthy control sera  4-  2 SD. Uptake <2 SD below the 
mean is considered  inhibitory. 
With  FB  as  the  target  cell  (Fig.  6a),  inhibition was  seen  in the  serum  from  one 
patient  with  active  polyarteritis;  the  remaining sera  showed  no  inhibitory activity. 
Using SMC,  no  sera  contained  inhibitory activity  (Fig.  6b).  With  EC,  one serum 
from the rheumatic disease control group inhibited 3HTdR  uptake  (the patient with M.  B.  KAHALEH, G.  K.  SHERER,  AND  E.  C.  LEROY  1333 
dermatomyositis);  in  the  scleroderma  group,  21  sera  did  not  manifest  inhibitory 
activity, whereas the remaining 31 sera markedly inhibited EC aHTdR uptake (Fig. 
6c).  Serum inhibitory activity has been observed to fluctuate directly with disease 
activity that was determined clinically in a  few patients followed prospectively (e.g. 
patient LL, Fig.  1). In the Raynaud's group, 8 sera did not inhibit aHTdR uptake, 
although  11  did.  One of the  11  patients with serum-inhibiting activity developed 
scleroderma 6 mo after the initial serum determination. 
Discussion 
Functional  and  structural  vascular  lesions  have  been  observed  in  the  organs 
involved in seleroderma, including reduction in the number of capillaries, telangiec- 
tatic vessels,  thickening of arterial walls, and intimal fibrosis of small arteries  (11). 
The cause of these changes is not clear. In the present study, using in vitro techniques, 
EC-specific cytotoxic activity has been observed in the plasma and sera of patients 
with scleroderma and Raynaud's syndrome. The cytotoxicity observed is not a result 
of a  deficiency of nutrient factors, as shown by serum-mixing experiments. Partial 
characterization indicates a heat-stable, nondialyzable activity which migrates on gel 
filtration with albumin. 
The endothelial and smooth muscle cells, and, more recently, fibroblasts, used in 
this study were obtained from the same tissue source and, presumably, share common 
transplantation and other surface antigens. The selective cytotoxicity observed in this 
study is cell type-specific (EC) and not tissue-specific. 
Arteriolar and capillary endothelia may be the primary target cell populations in 
scleroderma; the cells used in this study are venous in origin because techniques for 
isolating endothelial  cells  in  quantity  from  capillaries  or  small  arterioles  are  not 
satisfactory. Differences may exist among venous, arteriolar, and capillary endothelia. 
Subtle morphological, functional, and permeability differences have been described. 
Huttner (12) demonstrated that arterial endothelium, in contrast to capillary endo- 
thelium,  is  linked  together  by  highly interdigitated  cell junctions  that  appear  to 
exclude molecules of 40,000 daltons or larger. Whether or not the present cytotoxic 
activity  would  show  differential  effects  on  different  vascular  EC  remains  to  be 
determined. Scleroderma vascular disease involves certain sites in the vascular tree, 
suggesting the importance of local tissue factors for propagation of the disease. 
The arterial lesion in scleroderma is similar to those seen in malignant hypertension, 
thrombotic microangiopathies, and renal allograft rejection. In malignant hyperten- 
sion, endothelial injury and increased permeability may play a role in the pathogenesis 
of the vascular lesion (13).  Anti-endothelial-cell antibodies have been demonstrated 
and are considered to play a role in the pathogenesis of thrombotic microangiopathies 
(hemolytic-uremic syndrome, postpartum renal failure, and thrombotic thrombocy- 
topenic purpura)  (14).  Endothelial injury to the graft by anti-endothelial-cell anti- 
body, in addition to cellular immunity, has been implicated as a mechanism of renal 
allograft rejection (15). In disorders characterized by endothelial damage and vascular 
repair, the particular disease entity might depend more on the severity and chronicity 
of the vascular insult than the specific injurious agent. 
Many theories exist regarding the etiology and pathogenesis of scleroderma: endo- 
crine dysfunction, nervous disorder, infection, physical trauma of various types, and 
immune factors (16).  Many, if not all, of the manifestations of scleroderma can be 
explained on the basis of functional and structural vascular compromise after repeated 1334  ENDOTHELIAL INJURY IN SCLERODERMA 
vascular  insults,  subsequent  healing  of vascular  walls  with  proliferative  vascular 
response, and luminal narrowing. The coagulation cascade may be triggered by the 
intimal  lesion, leading to fibrin deposition, reduced blood flow, and local ischemia. 
The initial events that  occur after endothelial injury involve platelet  adherence, 
aggregation,  and  release  at  the  site  of exposed  subendothelium.  These events  are 
observed after acute (17, 18) or chronic endothelial injury (19). Release of vasoactive 
amines leads to increased microvascular permeability as a  result of EC contraction 
(20). Caplan  (21), using dye labeling and tritiated thymidine incorporation, showed 
that  sites  of increased  permeability  are  usually  associated  with  sites  of increased 
thymidine labeling. The puffy, or edematous, phase of scleroderma may be the clinical 
expression of increased  vascular permeability.  Platelets also release a  factor which 
promotes proliferation of smooth muscle cells in vitro (22). In experimental EC injury, 
SMC respond to the injury by migration to the intima followed by proliferation (23). 
In scleroderma vascular lesions, uhrastructural studies characterize the cell involved 
in intimal thickening as having smooth muscle-like features (4). 
A  variety of substances are known to induce endothelial damage: cholesterol (24), 
bile  acids  (25),  angiotensin  (26),  homocystine  (19),  endotoxin  (27),  and  immune 
complexes (28). It is important to identify the factor in scleroderma serum that injures 
endothelial cells; it is equally important to identify factors that promote endothelial 
cell proliferation. In this manner, a rational approach to the therapy of scleroderma 
might be designed. 
Summary 
Functional  and  structural  vascular  lesions  have  been  observed  in  the  organs 
involved in scleroderma. The etiology of these vascular changes is poorly understood. 
The ability to isolate, characterize, and maintain endothelial cells in vitro provides a 
target cell population to study endothelial damage in scleroderma. The present report 
describes the effect of scleroderma serum on endothelial, smooth muscle, and fibroblast 
cell types. Sera from patients with scleroderma (31/52) and Raynaud's syndrome (11/ 
19) contain cytotoxic activity, specific for endothelial cells, which  is nondialyzable, 
heat-stable, and elutes with albumin on gel-filtration chromatography. 
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